These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24853169)

  • 21. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.
    Molina-Morant D; Fernández ML; Bosch-Nicolau P; Sulleiro E; Bangher M; Salvador F; Sanchez-Montalva A; Ribeiro ALP; de Paula AMB; Eloi S; Correa-Oliveira R; Villar JC; Sosa-Estani S; Molina I
    Trials; 2020 Apr; 21(1):328. PubMed ID: 32293523
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Benznidazole treatment safety: the Médecins Sans Frontières experience in a large cohort of Bolivian patients with Chagas' disease.
    Sperandio da Silva GM; Mediano MFF; Hasslocher-Moreno AM; Holanda MT; Silvestre de Sousa A; Sangenis LHC; Brasil PEAAD; Mejía RA; Fux CP; Cubides JC; Saraiva RM; Brum-Soares LM
    J Antimicrob Chemother; 2017 Sep; 72(9):2596-2601. PubMed ID: 28645201
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
    Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
    Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pediatric clinical pharmacology studies in Chagas disease: focus on Argentina.
    Garcia-Bournissen F; Altcheh J; Giglio N; Mastrantonio G; Della Védova CO; Koren G
    Paediatr Drugs; 2009; 11(1):33-7. PubMed ID: 19127950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Arthritis and benznidazole: more closely related than we thought.
    Aldasoro E; Pinazo MJ; Oliveira I; Munoz J; Posada E; Requena-Méndez A; Serret N; Gascon J
    Antimicrob Agents Chemother; 2015 Jan; 59(1):727-9. PubMed ID: 25385100
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.
    de Jesus SM; Pinto L; Moreira FL; Nardotto GHB; Cristofoletti R; Perin L; Fonseca KDS; Barbêdo P; Bandeira LC; Vieira PMA; Carneiro CM
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
    Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
    J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical monitoring of drug association in experimental chemotherapy of Chagas' disease by a new HPLC-UV method.
    Moreira da Silva R; Oliveira LT; Silva Barcellos NM; de Souza J; de Lana M
    Antimicrob Agents Chemother; 2012 Jun; 56(6):3344-8. PubMed ID: 22450981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
    Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
    Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of cytokine profile and HLA association in benznidazole related cutaneous reactions in patients with Chagas disease.
    Salvador F; Sánchez-Montalvá A; Martínez-Gallo M; Sala-Cunill A; Viñas L; García-Prat M; Aparicio G; Sao Avilés A; Artaza MÁ; Ferrer B; Molina I
    Clin Infect Dis; 2015 Dec; 61(11):1688-94. PubMed ID: 26265500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.
    Álvarez MG; Hernández Y; Bertocchi G; Fernández M; Lococo B; Ramírez JC; Cura C; Albizu CL; Schijman A; Abril M; Sosa-Estani S; Viotti R
    Antimicrob Agents Chemother; 2016 Feb; 60(2):833-7. PubMed ID: 26596935
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Seronegative conversion after incomplete benznidazole treatment in chronic Chagas disease.
    Alvarez MG; Vigliano C; Lococo B; Petti M; Bertocchi G; Viotti R
    Trans R Soc Trop Med Hyg; 2012 Oct; 106(10):636-8. PubMed ID: 22898619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerance of benznidazole in a United States Chagas Disease clinic.
    Miller DA; Hernandez S; Rodriguez De Armas L; Eells SJ; Traina MM; Miller LG; Meymandi SK
    Clin Infect Dis; 2015 Apr; 60(8):1237-40. PubMed ID: 25601454
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
    Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
    Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does Progressive Introduction of Benznidazole Reduce the Chance of Adverse Events in the Treatment of Chagas Disease?
    Losada Galván I; Madrid Pascual O; Herrero-Martínez JM; Pérez-Ayala A; Lizasoain Hernández M
    Am J Trop Med Hyg; 2019 Jun; 100(6):1477-1481. PubMed ID: 30938285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
    Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Difference of effective antitrypanosomal dosages of benznidazole in mice and man. Chemotherapeutic and pharmacokinetic results.
    Richle RW; Raaflaub J
    Acta Trop; 1980 Sep; 37(3):257-61. PubMed ID: 6106364
    [No Abstract]   [Full Text] [Related]  

  • 38. Pharmacogenomic Profile and Adverse Drug Reactions in a Prospective Therapeutic Cohort of Chagas Disease Patients Treated with Benznidazole.
    Franco LAM; Moreira CHV; Buss LF; Oliveira LC; Martins RCR; Manuli ER; Lindoso JAL; Busch MP; Pereira AC; Sabino EC
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characteristics of Patients for Whom Benznidazole Was Released Through the CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease - United States, 2011-2018.
    Herwaldt BL; Dougherty CP; Allen CK; Jolly JP; Brown MN; Yu P; Yu Y
    MMWR Morb Mortal Wkly Rep; 2018 Jul; 67(29):803-805. PubMed ID: 30048425
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará].
    de Pontes VM; Souza Júnior AS; Cruz FM; Coelho HL; Dias AT; Coêlho IC; Oliveira Mde F
    Rev Soc Bras Med Trop; 2010; 43(2):182-7. PubMed ID: 20464150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.